Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026
Rhea-AI Summary
Bioventus (Nasdaq: BVS) will report fourth-quarter fiscal 2025 results before the market opens on March 5, 2026.
Management will host a conference call at 8:30 a.m. Eastern Time that day. According to Bioventus, investors can dial 1-833-636-0497 or join a live webcast and view materials at the company’s Investor Relations site. The webcast will be archived and available for replay through March 4, 2027.
Positive
- None.
Negative
- None.
News Market Reaction – BVS
On the day this news was published, BVS gained 0.34%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector scanner flagged CTKB and LAB moving up, while broader peers show mixed moves (e.g., TMCI up, AVNS/OFIX down). With BVS up 0.93% and peer_momentum_context.is_sector_move marked false, action appears more stock-specific.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Conference presentation | Neutral | +1.1% | Announced J.P. Morgan Healthcare Conference presentation and webcast details. |
| Nov 25 | Conference presentation | Neutral | +5.1% | Piper Sandler Healthcare Conference presentation and webcast availability. |
| Nov 04 | Quarterly earnings | Positive | +15.1% | Reported Q3 2025 results with improved EPS and reaffirmed guidance. |
| Oct 28 | Earnings date notice | Neutral | +3.4% | Set date and access details for Q3 2025 earnings call. |
| Sep 03 | Conference participation | Neutral | -2.5% | Announced participation in Morgan Stanley Global Healthcare Conference. |
Recent informational and conference announcements often coincided with modest positive moves, while the last reported earnings release saw a stronger upward reaction.
Over the last six months, Bioventus has focused on investor outreach and improving fundamentals. The company reported solid Q3 2025 earnings with revenue of $138.7M, positive GAAP EPS, and reaffirmed full-year guidance, which was followed by a 15.09% gain. Multiple conference presentations (Morgan Stanley, Piper Sandler, J.P. Morgan) and prior "to report" earnings notices showed generally constructive or modest price responses. Today’s announcement sets the timetable for Q4 FY 2025 results, continuing this cadence of regular investor communication.
Market Pulse Summary
This announcement schedules Bioventus’s Q4 fiscal 2025 results for release on March 5, 2026 and provides access details for the 8:30 a.m. ET call and webcast, which will remain archived until March 4, 2027. In recent quarters, the company reported improving profitability and reaffirmed guidance, which previously coincided with a 15.09% move after Q3 results. Investors may focus on upcoming revenue trends, margins, and guidance updates once the full Q4 data becomes available.
AI-generated analysis. Not financial advice.
DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March 5, 2026. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.
To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call.
A live webcast of the call and accompanying materials will also be provided on the “Investor Relations” section of the Company's website at https://ir.bioventus.com/. The webcast will be archived at the same site and available for replay until March 4, 2027.
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the Company on LinkedIn and X. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
Investor and Media Inquiries:
Dave Crawford
919-474-6787
Dave.Crawford@bioventus.com
FAQ
When will Bioventus (BVS) report Q4 fiscal 2025 results and what is the timing?
How can investors join the Bioventus (BVS) conference call on March 5, 2026?
Will Bioventus (BVS) provide a webcast and replay for the March 5, 2026 call?
What topics will Bioventus (BVS) management cover on the March 5, 2026 call?
Where can I find the Bioventus (BVS) call materials and replay after March 5, 2026?
